1.24
7.83%
0.09
After Hours:
1.20
-0.04
-3.23%
I Mab Adr stock is traded at $1.24, with a volume of 490.94K.
It is up +7.83% in the last 24 hours and up +9.73% over the past month.
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$1.15
Open:
$1.17
24h Volume:
490.94K
Relative Volume:
2.05
Market Cap:
$96.20M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-0.3258
EPS:
-3.8057
Net Cash Flow:
$-167.78M
1W Performance:
+18.10%
1M Performance:
+9.73%
6M Performance:
-33.33%
1Y Performance:
-6.06%
I Mab Adr Stock (IMAB) Company Profile
I Mab Adr Stock (IMAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-09-21 | Initiated | Siebert Williams Shank | Buy |
Jun-02-21 | Initiated | Daiwa Securities | Buy |
Mar-15-21 | Initiated | Needham | Buy |
Mar-03-21 | Reiterated | H.C. Wainwright | Buy |
Feb-25-21 | Initiated | Piper Sandler | Overweight |
Dec-07-20 | Initiated | H.C. Wainwright | Buy |
Jul-27-20 | Initiated | Cantor Fitzgerald | Overweight |
Feb-12-20 | Initiated | China Renaissance | Buy |
Feb-11-20 | Initiated | Jefferies | Buy |
View All
I Mab Adr Stock (IMAB) Latest News
It makes sense and dollars to buy I-Mab ADR (IMAB) stock - SETE News
Ratio Revelations: I-Mab ADR (IMAB)’s Financial Metrics in the Spotlight - The Dwinnex
I-Mab ADR (IMAB) Stock: From Low to High in 52 Weeks - The InvestChronicle
IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com
Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com India
I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com
I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com India
Federal Hill Taphouse & Kitchen abruptly closes - WPRI.com
I-Mab ADR (IMAB)’s stock price in review: A technical analysis - US Post News
There is no doubt that I-Mab ADR (IMAB) ticks all the boxes. - SETE News
Earnings call: I-MAB Biopharma discusses pipeline progress and financials - Investing.com India
Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India
I-Mab appoints new chairman and interim CEO - Investing.com
2024-07-15 | I-Mab Announces Leadership Transitions | NDAQ:IMAB | Press Release - Stockhouse Publishing
Financial Health Report: I-Mab ADR (IMAB)'s Ratios Tell a Tale – DWinneX - The Dwinnex
Teva Acquires Rights to Oncology Biosimilar Candidates - Yahoo News UK
It is Poised to be a Bull Market for I-Mab ADR (IMAB) – Sete News - SETE News
I-Mab names new Chief Medical Officer to enhance oncology pipeline - Investing.com India
I-Mab names new Chief Medical Officer to enhance oncology pipeline By Investing.com - Investing.com
I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks
Analysts review I-Mab ADR's rating – Knox Daily - Knox Daily
I-Mab and Bristol Myers team up for cancer drug trial By Investing.com - Investing.com
Watch this stock's price performance: I-Mab ADR (NASDAQ:IMAB) – US Post News - US Post News
I-Mab ADR Inc. (IMAB) Price Performance: A Technical Analysis Perspective - The InvestChronicle
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK
Check out these key findings about I-Mab ADR (IMAB) – Sete News - SETE News
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - GlobeNewswire Inc.
AbbVie Partners With Chinese Biotech for Cancer Candidate - Yahoo News NZ
(IMAB)Analyzing I-MAB's Short Interest By Benzinga - Investing.com UK
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks - Yahoo Lifestyle UK
Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate ProtectionTipRanks.com - TipRanks
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks - Yahoo Movies UK
I-Mab Announces CMO Transition, Interim Successor NamedTipRanks.com - TipRanks
I-Mab Finalizes Divestiture and Resolves ObligationsTipRanks.com - TipRanks
Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature.com
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - PR Newswire
Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis - Nature.com
Market Brief: Will the December CPI Report Help Further Tame Inflation Fears? - Morningstar
Morningstar’s Best- and Worst-Performing Stocks: 2022 - Morningstar
The Cheapest Stock in the World - Morningstar.ca
10 of the Cheapest Stocks of 2022 - Morningstar
Why Are Some China Healthcare Stocks Up 50%? - hk.morningstar.com
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage - Nature.com
The Best- and Worst-Performing Stocks: Q3 2022 - Morningstar
Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket By Benzinga - Investing.com UK
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal - Yahoo New Zealand News
AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody ... - ScienceDirect.com
I Mab Adr Stock (IMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):